​

MoonLake Immunotherapeutics Stock (NASDAQ:MLTX)

ForecastOwnershipFinancialsChartTranscripts

Previous Close

$14.94

52W Range

$5.95 - $62.75

50D Avg

$17.60

200D Avg

$16.91

Market Cap

$1.15B

Avg Vol (3M)

$1.30M

Beta

1.04

Div Yield

-

MLTX Company Profile

MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CH

Employees

130

IPO Date

Oct 20, 2020

Website

MLTX Performance

MLTX Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income-$-143.09M$-54.12M
Net Income$-229.10M$-118.94M$-36.01M
EBITDA$-219.85M$-141.71M$-53.75M
Basic EPS$-3.53$-1.89$-0.73
Diluted EPS$-3.53$-1.89$-0.73

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q1 23Sep 29, 25 | 8:45 PM

Peer Comparison

TickerCompany
AVBPArriVent BioPharma, Inc.
ABSIAbsci Corporation
ERASErasca, Inc.
RGNXREGENXBIO Inc.
VSTMVerastem, Inc.
OLMAOlema Pharmaceuticals, Inc.
CTMXCytomX Therapeutics, Inc.
MGTXMeiraGTx Holdings plc
MBXMBX Biosciences, Inc. Common Stock
VTYXVentyx Biosciences, Inc.